Advanced Urothelial Carcinoma
Advertisement
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
The panel shares their hopes for the future of bladder cancer treatment.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
The panel shares lessons learned from the phase THOR study.
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
The panel discusses the CheckMate 901 study results.
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
The panel discusses the "buzz" around the EV-302 study.
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Dr. Evan Yu opines on whether the EV-302 and CheckMate 901 data are practice-changing and when to recommend each combo.
This is the first trial that has shown an OS benefit improvement over chemo in the 1L mUC setting, a landmark achievement.
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Erdafitinib was found to significantly improve OS and boost benefit over chemotherapy in patients with FGFRalt advanced/mUC.
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
Paclitaxel administered with tremelimumab provided encouraging antitumor activity with a manageable safety profile.
The practice-changing results were presented at ESMO 2023.
Nivolumab plus gemcitabine-cisplatin demonstrated meaningful improvements in OS and PFS as first-line treatment of mUC.
The combination of sacituzumab govitecan plus enfortumab vedotin was found to be safe, and provides a high ORR.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.